JAKARTA, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - The Indonesia Carbon Capture and Storage Center (ICCSC) is organizing The 3rd International & Indonesia CCS Forum 2025, an international-scale forum aimed at accelerating the development of Carbon Capture and Storage (CCS) technology as a key pillar toward a green economy and sustainable growth in Indonesia. The event will take place on October 7-8, 2025, at Hotel Mulia, Jakarta, featuring over 100 global speakers from various sectors.Belladonna Troxylon Maulianda, Executive Director of ICCSC, emphasized that this forum is designed as a strategic platform to bring together global stakeholders, including governments, industry players, academics, and investors. "CCS plays a crucial role in reducing carbon emissions and supporting Indonesia's net-zero targets. Through this forum, we aim to strengthen global collaboration to address challenges and leverage opportunities in CCS development," said Belladonna.The forum's theme, "Advancing Indonesia as a CCS Hub Leader in the Asia Pacific: Achieving Net Zero and Economic Growth", reflects a shared commitment to driving sustainable growth through clean energy. "We hope this event will generate innovative solutions and policy recommendations to accelerate CCS development in Indonesia and globally," she continued.Evan Lukas, Chairman of the Organizing Committee for The 3rd IICCS Forum 2025, explained that this event will feature various exciting programs, including high-level panel discussions, exhibitions of the latest technology, and strategic networking sessions. "This forum is not only a platform for sharing knowledge but also a place for the birth of strategic partnerships and innovative solutions to global challenges in CCS development," said Evan."We invite all stakeholders, including the government, industry players, and the community, to actively participate in this forum. Together, we can build a network of regional CCS hub towards a low-carbon future and support energy transition" added Evan.ICCSC hopes this forum can become a catalyst for strengthening Indonesia's position as a global leader for regional CCS hub that decarbonize heavy industries, while continuing to meet energy demand and grow economies.Elen Setiadi, Deputy Minister for Energy and Mineral Resources, Coordinating Ministry for Economic Affairs of The Republic of Indonesia expressed appreciation for the forum's organization. "The government fully supports this event as part of efforts to achieve energy transition and net-zero emission targets. CCS is one of the key solutions in Indonesia's clean energy transition," said Elen.The 3rd International & Indonesia CCS Forum 2025 also offers participants the opportunity to interact directly with industry leaders, experts, and policymakers. In addition to the main programs, the event will showcase the latest CCS technology exhibitions featuring innovations from global companies.The ICCSC invites all stakeholders, including strategic partners, industry associations, government representatives, and media, to join this forum. The event is not only a moment for discussion but also for taking concrete steps toward realizing a sustainable clean energy future.For more information on The 3rd International & Indonesia CCS Forum 2025, visit the official website: www.iiccsforum.com About IICCSThe International & Indonesia Carbon Capture and Storage Center (IICCS) is a platform dedicated to promoting CCS technology and facilitating collaboration between governments and industries in addressing climate change through CCS implementation. About ICCSCThe Indonesia Carbon Capture and Storage Center (ICCSC) is a community of experts from various industry, including engineering, science, policy, and business, united by a shared commitment to finding practical solutions to CO2 emission challenges. Through research, innovation, and advocacy, we strive to accelerate carbon capture and storage development in Indonesia and position the country as a Regional CCS Hub. Visit iccscenter.com.Media Contact:info@iccscenter.com+62 878 8721 3208 Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) has approved the Company’s application to remove the “B” marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. “We are very pleased that Everest Medicines has satisfied the market capitalization/revenue test under Rule 8.05(3) of the Listing Rules and successfully removed the 'B' marker - a significant milestone for the Company in the capital markets that could lead to wider investor participation.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "Moving forward, we will continue to deepen our 'dual-engine strategy', enhancing our commercial excellence and advance our first-in-class and best-in-class assets with global rights to maximize synergies. With global rights to EVER001, we will actively explore partnership opportunities outside of China to leverage international expertise and optimize commercial value, while further enhancing Everest’s global visibility and presence. Everest will leverage its established efficient commercial platform to solidify our position in key therapeutic areas, advance innovation on our mRNA platform, and strive to become a leading biopharma in the Asia-Pacific region by 2030.The removal of the “B” marker reflects a comprehensive evaluation of Everest Medicines’ robust R&D pipeline, commercialization capabilities, and overall business fundamentals. Listed on the Stock Exchange in October 2020, Everest has adopted a “dual-engine” strategy, focusing on high-value therapeutic areas while striving to develop first-in-class or best-in-class innovative treatments. The company has established a strong and synergistic platform across nephrology, infectious diseases, and autoimmune diseases, with three commercialized products already driving rapid revenue growth.According to the company’s 2024 financial results, total revenue reached RMB706.7 million, representing a 461% year-over-year increase and exceeding our revenue guidance of RMB700 million, and achieved commercial-level profitability for the full year of 2024.NEFECON®, as the only approved IgAN therapy in China, generated RMB353.4 million in revenue for the year, representing a year-over-year increase of 1,581%. NEFECON® was also included in China’s National Reimbursement Drug List (NRDL), effective January 1, 2025. As the first-in-class fluorocycline antibiotic, XERAVA® (eravacycline) maintained robust growth with generated RMB352.8 million in revenue in 2024, representing a 256% year-on-year increase. VELSIPITY® (etrasimod), a best-in-class therapy for autoimmune diseases, has been received regulatory approvals in Macau and Singapore, the product was subsequently commercially launched in December in Guangdong province under the “Hong Kong and Macau Medicine and Equipment Connect” policy. In parallel, New Drug Applications (NDAs) for VELSIPITY® have been officially accepted in both mainland China and Hong Kong in December 2024.EVER001, for which Everest holds global rights, delivered positive results from the preliminary analysis of our Phase 1b/2a trial and is progressing steadily through global development. EVM16, our personalized therapeutic mRNA cancer vaccine, completed first patient dosing in an investigator-initiated clinical trial (IIT) in March 2025. EVM14, our off-the-shelf tumor-associated antigen (TAA) vaccine, received Investigational New Drug (IND) approval from the U.S. FDA, and we plan to submit an IND application to China’s NMPA in the first half of this year. The in vivo CAR-T program is expected to achieve preclinical candidate milestone later this year. These programs are supported by our commercial-scale, GMP-compliant manufacturing facility in Jiashan, Zhejiang, which provides integrated R&D, production, and commercialization capabilities across mRNA and other pipeline platforms. Copyright 2025 ACN Newswire via SeaPRwire.com.

Key Highlights:- Green jobs in Singapore show 27% year-on-year growth with 12% month-on-month increase in March '25- Engineering, Construction & Infrastructure sector leads sustainability hiring with 29% share of green jobs- Consulting & Strategy sector accounts for 11% of sustainability-focused positions- ESG Analyst emerges as the role with the highest growth in demand 28% year-on-year - Singapore's green job sector projected to grow by 11% in 2025SINGAPORE, Apr 23, 2025 - (ACN Newswire via SeaPRwire.com) - Jobs platform, foundit (formerly Monster APAC & ME), today published the foundit Earth Day Special Singapore Report as part of the foundit Insights Tracker (fit). The report highlights significant growth in sustainability-driven hiring across Singapore's employment landscape.The tracker reveals an overall year-on-year (YoY) growth of 27% in green jobs, with a positive month-on-month (MoM) increase of 12% in March 2025, building on the 17% growth seen in February."Singapore’s green job market is witnessing remarkable growth," said V Suresh, CEO of foundit. "Our Earth Day Special report reveals a 27% year-on-year surge in green job opportunities, underscoring the nation’s steadfast commitment to sustainability and environmental stewardship. Pivotal sectors such as Engineering, Construction, and Sustainable Finance are spearheading this transition, driving substantial and lasting impact. This upward trend not only mirrors the evolving demands of the labour market but also resonates strongly with the objectives of Singapore’s Green Plan 2030, reaffirming sustainability as a cornerstone of the country’s long-term economic vision.”Engineering, Construction and Consulting sectors lead sustainability hiringThe Engineering, Construction & Infrastructure sector has emerged as the frontrunner in sustainability-focused hiring, accounting for 29% of all green job opportunities across monitored industries. This dominance reflects Singapore's commitment to eco-friendly urban development and sustainable infrastructure projects. Representing 11% of green job postings, the Consulting & Strategy sector is gaining momentum, driven by growing demand for sustainability consultants and environmental strategists as organisations integrate ESG frameworks into their operations.Education and Manufacturing & Production sectors each contribute 7% of sustainability-focused positions, highlighting increased focus on workforce reskilling and the transition toward cleaner production practices.Energy and Research & Technology sectors each account for 6% of green job opportunities, supporting innovations in renewables, green hydrogen, and sustainable R&D initiatives across Singapore.ESG and Renewable Energy professionals lead demand among sustainability rolesIn terms of sustainability-focused roles, ESG Analysts witnessed the highest growth with a 28% year-on-year increase, underscoring the rising importance of environmental, social, and governance considerations in business operations.Sustainability Consultants followed closely with 24% year-on-year growth, while Renewable Energy Engineers showed strong demand with 22% year-on-year growth, reflecting Singapore's push toward clean energy alternatives.Other high-growth roles include Green Supply Chain Managers (+19%), Environmental Policy Officers (+16%), Carbon Credit Analysts (+14%), and Climate Risk Specialists (+13%), indicating broad demand across sustainability functions.The report highlights evolving skill requirements, with employers increasingly seeking cross-functional expertise that blends engineering, finance, policy, and digital proficiency to meet regulatory and ESG expectations.Looking ahead, the green job sector in Singapore is projected to grow by 11% in 2025, with renewable energy, electric mobility, and green infrastructure identified as key growth drivers.The foundit Insights Tracker is a comprehensive monthly analysis of online job posting activity conducted by jobs platform, foundit. Based on a real-time review of millions of employer job opportunities culled from a large, representative selection of online career outlets, the foundit Insights Tracker (FIT) presents a snapshot of employer online recruitment activity nationwide.About foundit - APAC & Middle Eastfoundit, formerly Monster (APAC & ME), is Asia’s leading jobs and talent platform offering comprehensive employment solutions to recruiters and job seekers across APAC & ME. In addition to its innovative AI-powered job search, foundit offers e-learning, assessments, and services related to resume creation and interview preparation. foundit has connected over 120 million job seekers across 18 countries with the right job roles and upskilling opportunities. Over the last two decades, the company has been a leader in the world of recruitment solutions and has launched cutting-edge tools to give recruiters access to passive candidates in addition to active ones. With its advanced technology, foundit is efficiently bridging the talent gap across industry verticals, experience levels, and geographies.Today, foundit is committed to enabling and connecting the right talent with the right opportunities by harnessing the power of deep tech to sharpen hyper-personalised job searches and offer precision hiring.To learn more about, foundit in APAC & Gulf, visit: www.foundit.sg |www.foundit.com.ph | www.foundit.my | www.foundit.in | www.founditgulf.com | http://www.foundit.hk | www.foundit.id For media inquiries or further information, please contactNamrata SharmaNamrata.sharma@adfactorspr.comContact number - +65 81383034 Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) – In recent years, with the launch of top-level design for nuclear medicines and the implementation of supporting policies, the domestic nuclear medicine industry has ushered in a golden period of development. According to the data analysis of BCC Research, there will be a growth in the global nuclear medicine market from $12.6 billion in 2023 to $21 billion by the end of 2029, with a compound annual growth rate (CAGR) of 8.29% during the forecast period from 2024 to 2029. Meanwhile, Medraysintell, a market intelligence agency specializing in radiotherapy and nuclear medicine, predicts that there will be a growth of about $30 billion in the global nuclear medicine market in 2030.As a leading nuclear medicine company in China, CIRC (01763.HK) recently disclosed its annual report for 2024 as of December 31st. In 2024, CIRC achieved a remarkable growth in revenue and net profit, which not only delivered a satisfactory answer on the performance level, but also showed a strong technical transformation capability in nuclear medicine research and development.Year-by-year growth facilitated nuclear medical equipment to become a new engineAccording to the financial data, CIRC achieved revenue of RMB 7.575 billion in 2024, with a year-on-year increase of 14.2%, and the net profit of RMB 880 million, with a year-on-year increase of 13.3%.From the perspective of branch business, all fields have blossomed in an all-round way. As the core pillar of the company, the nuclear medicine business achieved revenue of RMB 4.168 billion, accounting for 55% of the total revenue. Among them, the income of imaging diagnosis and therapeutic radiopharmaceuticals increased by 4.1% year-on-year, and the distribution of medical centers all over the country achieved remarkable results. The income of Technetium-labeled medicines increased by 8.7% year-on-year. The breath test business continued to maintain a stable high market share, achieving revenue of RMB 2.35 billion, by a year-on-year increase of 1.1%.It is worth noting that in 2024, CIRC accelerated the localization of high-end radiotherapy equipment, and nuclear medical equipment and related services became the new engine of growth, with revenue reaching RMB 1.223 billion, a year-on-year increase of 31.0%. The new generation of Precision radiation therapy planning system was successfully approved for medical device registration certificate, and the world’s first spiral tomotherapy system, Tomo C, was delivered to Shandong Cancer Hospital for installation, which was successfully selected intothe 2024 high-end medical equipment promotion and application project of two ministries and commissions (Ministry of Industry and Information Technology/National Health Commission) and Tianjin First (Set) Major Technical Equipment Promotion and Application Guidance Catalog (Version 2024), with sales during the year leading in the domestic market.CIRC recorded RMB 716.1 million in revenue from radioactive source products, representing a year-on-year increase of 22.2%. Gamma knife source and non-destructive testing radioactive source continued to maintain a stable and high market share. CNNC Qinshan Isotope successfully obtained the Class A radiation safety license, and the cobalt-60 radioactive source production line delivered 2 million curies.40-year solid accumulation in nuclear technology laid a solid foundationAs the main body of the nuclear technology application industry of CNNC, CIRC has been accumulated in the industry for over 40 years, forming a “6+N” industrial layout with six major businesses as the core, including nuclides, nuclear medicines, nuclear medical equipment, integrated solution for nuclear medicine, radioactive source and application, and irradiation application. During the Reporting Period, CIRC achieved 224 patent authorizations, with a total of 969 valid patents, and continued to maintain the leading position of the R&D investment intensity in the industry.In the field of nuclear medicine research and development, CIRC has demonstrated a strong technical capability from research results turned into technologies. Sodium fluorine-18 injection obtained the drug registration certificate from the National Medical Products Administration and was approved for marketing, filling the market gap of PET diagnostic imaging agent in the field of bone imaging in China. Iodine-131-MIBG injection is close to the end of Phase III clinical trial. After the drug is launched, it will provide a new diagnostic method for neuroendocrine tumors such as pheochromocytoma and neuroblastoma. It is worth noting that CIRC has proactively laid out integrated diagnosis and treatment drugs, and the research and development of Lutetium-177oxyoctreotide injection is progressing smoothly, marking a strategic upgrade from simple diagnosis to precise diagnosis and treatment.In addition to stabilizing the base of nuclear medicine, CIRC has gradually increased its emphasis on nuclear medical equipment. According to the sales data in recent years, the income of nuclear medical equipment has steadily increased. In 2024, a new generation of Gamma Knife was approved, which integrated CBCT image guidance, six-dimensional bed auto-correction, and other intelligent technologies, and the treatment efficiency was improved by 30%. In the Class A large-scale medical equipment market, CIRC occupies an absolute dominant position through its holding subsidiary, CNNC ACCURAY. In February this year, 19 of the 28 high-end radiotherapy equipment in the second round of Class A large-scale medical equipment licensing list released by the National Health Commission came from CNNC ACCURAY, accounting for 68% of the market. It is worth noting that the breakthroughs in the fields of Cobalt-60-based Stereotactic Therapy System also promote the localization of radiotherapy equipment.Facing the explosive growth of the nuclear medicine market, CIRC Accelerated Pharmaceutical Center continues to expand its nationwide network layout. In 2024, a new positron emission drug production line has been added in Lanzhou, with a total of 23 lines put into operation; Newly added Fuzhou Technetium Drug Production Line, with a total of 27 units put into operation. CIRC has built the first 10,000 Curie level lutetium-177 production line and a thousand level germanium-gallium [68Ge-68Ga] generator production line in the country, achieving a breakthrough in the localization of high-end nuclides.It is worth noting that CIRC has created a hierarchical innovation ecosystem through the "Parent-Subsidiary Collaboration" model. In 2024, its subsidiaries, CNNC HEADWAY (breath test) and CNNC Chengdu Gaotong (nuclide), were awarded the national level specialized, refined, and new "little giants" enterprise, bringing the total number of specialized, refined, and new enterprises under CIRC to 18. Among them, CNNC HEADWAY dominates the breath testing market with its integrated solution of "medicine box+instrument", while CNNC Chengdu Gaotong has become a benchmark in the field of nuclear technology application through its full chain layout of "Nuclide-Drug-Equipment". This innovative system, resembling an "Aircraft carrier battle group", provides sustainable momentum for the company's long-term growth.Expanding Development Space with Globalization LayoutAs the main force of CNNC Group's march towards people's life and health science and technology and the main channel for the transformation of advanced nuclear science and technology achievements, CIRC responds to the Group's "Overall&Coordination" internationalization strategy and the national "the Belt and Road" initiative, vigorously promotes the internationalization strategy and constantly expands overseas markets. By 2024, the export revenue will reach RMB 627 million, and the products will be exported to dozens of countries and regions such as Brazil, Peru, and Nigeria.At the beginning of this year, we successfully signed a contract for the supply of equipment for a million curies design source gamma irradiation station in Bangladesh. This is another equipment supply project for irradiation stations that has landed after winning the bid for the Bangladesh Institute of Nuclear Agriculture's design source gamma irradiation station project in 2024. After its completion and operation, the irradiation station will mainly serve the irradiation sterilization of medical products in Bangladesh, significantly improving the quality level and production processing capacity of local medical products, assisting the development of Bangladesh's medical industry, and benefiting local people's livelihoods.In Nigeria, CIRC successfully signed a contract for the overall supply of nuclear medical equipment, achieving the first successful landing of the Group's nuclear medical equipment overall supply project. In addition, CIRC actively expands into the ASEAN market and successfully exports cold chain drugs to Thailand; We have also signed strategic cooperation agreements with multiple entities in Brazil to support the signing of a memorandum of understanding on strategic cooperation in the field of nuclear technology applications between the National Atomic Energy Agency and Brazil.ConclusionAgainst the backdrop of policy support and sustained market demand, CIRC stated to focus on the "Do as the Demard of the Country" and further deepen the coordinated development of nuclear medicine and high-end equipment around the "Healthy China" strategic framework. According to its 2025 plan, key projects such as Qinshan Isotope Base, Phase I of Jiajiang Radioactive Source Base, and Phase I of North China Pharmaceutical Base will be promoted according to milestones, involving nuclide production, radioactive source manufacturing, and pharmaceutical supply chain layout. At the same time, CIRC will enhance its digital diagnosis and treatment service capabilities through the iteration of smart nuclear medicine projects, and plans to launch no less than 3 intelligent systems within this year.At the international level, CIRC will continue the market expansion strategy along the "the Belt and Road", rely on the existing business models such as radiation station equipment export, nuclear medical equipment overall solution output, focus on the cooperation in South America, Southeast Asia, the Middle East, North Africa and other regional markets, and further improve the global market penetration rate in the future or through localized cooperation.The management of the Company stated that in 2025, CIRC will continue to strengthen technological innovation, improve the modern industrial system, accelerate the cultivation and development of new quality productivity, continuously enhance core functions, improve core competitiveness, and accelerate the establishment of an internationally-renowned supply group of technology, product and service in isotope and radiation. Copyright 2025 ACN Newswire via SeaPRwire.com.

WELLINGTON, FL, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) - The 2025 U.S. Open Polo Championship®, played at the USPA National Polo Center (NPC) in Palm Beach County, showcased top-tier polo action from March 26 to April 20 and ended this Sunday with a thrilling Final win by La Dolfina Tamera over La Dolfina Catamount in a score of 12-8 in front of a record crowd.Agustina FondaLa Dolfina Tamera wins the U.S. Open Polo Championship® trophy.Watch the U.S. Open Polo Championship on ESPNHosted by legendary ESPN broadcaster Chris Fowler, the U.S. Open Polo Championship Final was played on the U.S. Polo Assn. Stadium Field, in front of an electric crowd. The game will be broadcast to a large global audience across multiple ESPN platforms, including ESPN2 on Saturday, April 26, at 10:30 AM EDT, as well as Primetime on ESPNews on Sunday, April 27. Check your local listing for air times.U.S. Polo Assn. Supports the Sport and Equine CharitiesAs the sport's most prestigious tournament in North America, the U.S. Open Polo Championship features some of the world's best polo players and equine athletes. Once again, the tournament was supported by U.S. Polo Assn., the official brand of the United States Polo Association (USPA), with U.S. Polo Assn. branded jerseys for teams, NPC staff uniforms, umpire outfitting, player prizes, and monetary donations to several local charities. Throughout the season, the global, sport-inspired brand has donated some $25,000 to polo charities and equine welfare, among others, including Homes for Horses Coalition, Museum of Polo and Hall of Fame, Polo for Life, Polo Players Support Group, Polo Pony Rescue, Polo Training Foundation, Replay Polo, Retired Racehorse Project, Vinceremos Therapeutic Riding Center, and Work to Ride Program."U.S. Polo Assn. is proud to once again support the U.S. Open Polo Championship, broadcast on ESPN platforms as one of the top sporting events of the Spring season alongside the Masters and Kentucky Derby," said J. Michael Prince, President and CEO of USPA Global, the company that manages and markets the multi-billion-dollar U.S. Polo Assn. brand. "It's an honor to have legendary ESPN broadcaster Chris Fowler as the host this year, alongside Kenny Rice and Adam Snow, bringing more access and awareness to the sport of polo as we continue to reach more and more sports fans and consumers around the world."An Electric Game Watched Live by a Record-Breaking CrowdThousands of fans at NPC witnessed the action-packed final game of the Gauntlet of Polo® tournament series, which included the C.V. Whitney Cup®, the USPA Gold Cup®, and the U.S. Open Polo Championship. In a year that delivered record-breaking crowds week in and week out, the thrilling final was filled with great plays from the world's best players on both teams, La Dolfina Tamera featuring 10-goal player Adolfo Cambiaso; Diego Cavanagh; Matt Coppola; and Alejandro Poma, and La Dolfina Catamount featuring 10-goal player Poroto Cambiaso; Jesse Bray; Rufino Merlos and Scott Devon. For the second year in a row, the U.S. Open Polo Championship Final presented an epic showdown between two of the world's top polo players who are also father and son.Adolfo, age 50, who has been defeated in the last two U.S. Open Finals, the last one being to his son, Poroto, age 19, reclaimed victory in this game to take home his 10th U.S. Open title. It was just this week that Adolfo turned 50, thus reclaiming the championship trophy as his perfect birthday present. Adolfo is considered the best polo player in history, having also won more than 17 titles in the Argentine Open Polo Championship, and is considered the "Greatest of All Time (GOAT)" beside other sports icons such as Tiger Woods, Michael Jordan, and Tom Brady.Adolfo Cambiaso, Age 50, Defeats Son Poroto Cambiaso, Age 19, Wins Back TrophyLa Dolfina Catamount came out strong at the beginning of chukker 1, but La Dolfina Tamera soon took the momentum and kept the game close. The score was tied at 6-6 after the 3rd chukker. After some clutch goals by Poma in chukkers 3,4, and 5 and an impressive long goal from Adolfo, Tamera continued to have the lead. Though Poroto scored an incredible 5 goals overall, and Bray scored in the 6th and final chukker, both of Catamount, to bring it to 11-8, there just wasn't enough time for a comeback. Tamera clinched their win with a thrilling goal by Coppola to make the final score 12-8. La Dolfina Tamera's Poma won MVP, scoring a team-high 4 goals, with Adolfo scoring 3 goals."Congratulations to La Dolfina Tamera on a remarkable victory in the U.S. Open Polo Championship," said Stewart Armstrong, Chairman of the USPA. "I would also like to thank and acknowledge all participating teams throughout the 2025 Season at NPC for leaving it all on the field for the sport.""Thank you to all of our patrons, players, sponsors, and sports fans for their passion and support for the sport of polo and the USPA this season," Armstrong added.The USPA National Polo Center, the Winter Equestrian Capital of the WorldGuests at NPC, the world's premier polo facility based in Palm Beach County, watched the action-packed match from many luxurious settings, including the sidelines, stadium boxes, tailgate tents, the grandstands, as well as from the U.S. Polo Assn. MVP Lounge, home to the iconic Sunday Polo Brunch. Sports fans also had exclusive on-site shopping opportunities at the flagship USPA Shop location, where limited-edition sport-luxury pieces in The Polo Club Collection and the U.S. Polo Assn. Global Collection were available for fans wanting to take home a piece of the sport of polo. New this year included a 4ocean branded custom-designed bracelet, an element of the longstanding partnership between the two brands, with 4Ocean being the Official Recycling Partner of the 2025 U.S. Open Polo Championship.Photo Credits: Agustina FondaLa Dolfina Tamera wins the U.S. Open Polo Championship® trophy.La Dolfina Tamera's Adolfo Cambiaso hooks the mallet of his son Poroto Cambiaso of La Dofina Catamount in a defensive play to ultimately win the U.S. Open Polo Championship® in a score of 12-8.The record-breaking crowd at the USPA National Polo Center (NPC) watching the heart-pounding U.S. Open Polo Championship® Final.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. Historic deals with ESPN in the United States and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, NBA, and MLB, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global and digital growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world.For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the USPA and manages the global, multi-billion-dollar U.S. Polo Assn. brand. Through its subsidiary, Global Polo Entertainment (GPE), USPA Global also manages Global Polo TV, which provides sports and lifestyle content. For more sports content, visit globalpolo.com.Contact InformationShannon StilsonVP, Sports Marketing & Mediasstilson@uspagl.com+001.561.227.6994Stacey KovalskyVice President, Global PR and Communicationsskovalsky@uspagl.com+001.561.790.8036SOURCE: U.S. Polo Assn.Related ImagesAgustina FondaLa Dolfina Tamera’s Adolfo Cambiaso hooks the mallet of his son Poroto Cambiaso of La Dofina Catamount in a defensive play to ultimately win the U.S. Open Polo Championship® in a score of 12-8.Agustina FondaThe record-breaking crowd at the USPA National Polo Center (NPC) watching the heart-pounding U.S. Open Polo Championship® Final. Copyright 2025 ACN Newswire via SeaPRwire.com.

Luxembourg, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination"). Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC ("Nutrecon"), and Gentle Technologies Corp ("Gentle Tech", and together with Bioceres Group and Nutrecon, the "Contributed Entities"), resulting in an enlarged corporate structure with Moolec as the parent company. In exchange, Moolec will issue a combination of up to 87 million newly issued shares and 5 million warrants to the shareholders of the Contributed Entities, as more fully described below in the Timing and Approvals section.Federico Trucco, Bioceres Group's board member and CEO of Bioceres Crop Solutions Corp commented: "The need to accelerate agricultural innovation to address current and future challenges, such as enhancing on-farm profitability and reducing environmental impact, is increasingly evident. Molecular farming, as exemplified by Moolec Science, offers a compelling solution to the challenge of balancing productivity and sustainability. For instance, what soybean yield technology can rival the direct production of 300kg of animal protein from a 3-ton-per-hectare crop?" He then finished: "Moolec's recent transformational transaction represents the kind of bold action needed to drive radical change in agriculture. Integrating technologies and capabilities, along with a holistic perspective on agricultural evolution, are essential for moving beyond incremental improvements. Scale and visibility, both of which are key aspects of this transaction, are crucial to achieving this goal. Bioceres is enthusiastic to be part of a larger, more ambitious Moolec, one that expands its focus from science in food ingredients to a comprehensive ‘cradle-to-cradle' approach."Juan Sartori, Founder and Chairman of Union Group remarked: "This is not just a strategic alignment of businesses, it's the creation of a new kind of company for the 21st century. By combining science, scale, and sustainability, Moolec is positioned to lead a global transformation in how we produce food, materials, and energy. I'm proud to support this vision and the exceptional teams bringing it to life."Following the closing of the Business Combination, Moolec will become uniquely positioned in the agricultural value-chain, with a powerful and validated technology discovery and development engine that can address in a cost-competitive way multiple upstream and downstream needs. Moolec's new value proposition will be centered around modifying or improving seeds and microbes to positively impact the way we utilize land and water resources, while preserving and/or improving human health.Alejandro Antalich, Chairman of Synbio Powerlabs® added: "This combination marks a defining moment for the bioeconomy. By integrating next-gen ingredients, biological ag solutions, and deep-tech manufacturing capabilities under one roof, we are building a company with unmatched scientific depth and commercial reach. Together, we aim to accelerate the shift toward a more sustainable and resilient food system, one that works in harmony with nature, rather than against it."As stated in their most recent annual reports, the companies and brands, which will be controlled or co-controlled by Moolec at the closing of the Business Combination, manage a portfolio of more than 800 patents (or patent applications) and over 550 product registrations, which translates into more than half a billion dollars of goods and services sold in their last fiscal year, to customers in more than 50 different countries.José López Lecube, CFO and Director of Moolec commented: "This transformative transaction marks a new stage for Moolec, positioning the company for growth within a broader organization that facilitates synergies on multiple levels. Becoming part of a larger organization will enable cost efficiencies and significant revenue increase as well as product portfolio diversification. It will also enlarge our investor base, providing the company with new stakeholders who support Moolec's new and more diversified business."Finally, as reported Mr. Gastón Paladini will step down as Chief Executive Officer (CEO), Director and Chairman of the Board, effective immediately following Moolec's Extraordinary General Meeting ("EGM") to be held on April 22, 2025.Key highlights:Ingredient Innovation: Moolec will continue to develop its flagship molecular farming products such as Piggy Sooy™ and GLASO™, while integrating Mycofood™ under the Eternal® brand from Nutrecon.Biological Ag Expansion: Through Bioceres Group, Moolec will now offer upstream technologies for regenerative agriculture, including biological inputs and climate-resilient seeds like Rizobacter®, ProFarm®, and the HB4® trait.Advanced R&D and Services: Leveraging expanded infrastructure, Moolec will offer R&D, CDMO, and regulatory services under the Agrality® and Synbio Powerlabs® brands, which are controlled or co-controlled by Bioceres Group and Nutrecon, respectively.Emerging Tech & Equipment: The Company will also expand its reach into emerging technologies for grain and biomass transformation, especially in the biomaterials space, as well as new concepts on farm equipment, integrating material science, electric mobility, and autonomy. These emerging opportunities are being pursued by Gentle Tech and Bioceres Group subsidiaries.Operational Synergies: The Business Combination is expected to result in significant cost synergies and an integrated management structure, which will be presented at or prior to closing of the Business Combination.Timing and ApprovalsThe Business Combination was unanimously approved by the Board of Directors of all the entities participating in the deal. It is expected to close during the second quarter of 2025 or thereafter, and it is subject to finalizing Moolec's reverse stock split process and re-domicile to the Cayman Islands among other customary closing conditions and regulatory approvals. This includes the approval by Moolec's shareholders at a special meeting of shareholders of proposals relating to the Business Combination. Given that the transaction was originally proposed by about 70% of Moolec's current shareholders, the Company expects strong shareholder support for the Business Combination approval.The Business Combination will be consummated through an equity exchange. Bioceres Group's shareholders will surrender their share ownership in Bioceres Group and will receive in exchange up to 80,590,280 shares of Moolec. The shareholders of 100% of Nutrecon and 50% of Gentle Tech will surrender their ownership in these two entities and will receive in exchange 6,475,000 shares of Moolec and 5,000,000 warrants of Moolec at a strike price of $2.00 per warrant, subject to adjustment based on the results of the reverse stock split process.The intrinsic value of the exchange ratio and the $2 strike price of warrants represent both a compelling premium to Moolec's current stock price, and a unique opportunity to assemble one of the most formidable public companies in the agricultural industry.Description of Contributed Entities and AssetsThe Contributed Entities consist of Bioceres Group and its subsidiaries, Nutrecon and its subsidiaries and Gentle Tech and its subsidiaries.Bioceres GroupBioceres Crop Solutions Corp. (NASDAQ: BIOX)Fully integrated provider of crop productivity solutions, including patented technologies for seeds and microbial agricultural inputs, as well as next generation crop nutrition and protection solutions. The company developed HB4® technology, which confers tolerance to climate changes in soybeans and wheat by allowing these crops to tolerate drought and soil salinity conditions. It also owns and licenses more than 570 products with approximately 750 patents and patent applications in the United States, Canada, Brazil, Argentina and other countries.Bioceres Tech Services (Agrality® & Inmet)Agrality® is a global agricultural services provider catering to agro-industrial companies worldwide. Their comprehensive service offerings encompass seed manufacturing and R&D, field-testing, and regulatory capabilities, ensuring their clients receive end-to-end solutions. Agrality's key assets include advanced seed production facilities, enabling high-quality seed development and production.Inmet specializes in the bio-transformation of agro-industrial residues, offering sustainable solutions for waste management in the agricultural sector. They utilize innovative technologies to convert agricultural waste into valuable products. Additionally, Inmet is involved in the production and assessment of bioplastics, contributing to the development of eco-friendly alternatives to conventional plastics.Nutrecon (Synbio Powerlabs®)Headquartered in Helsinki, Finland, Synbio Powerlabs® is an innovative early-stage biotechnology company specialized in research, development, and production of sustainable fungi-derived ingredients. With state-of-the-art laboratories and a pilot-to-industrial scale precision fermentation facility, the company operates uniquely as both a Research and Technology Organization ("RTO") and a Contract Development and Manufacturing Organization ("CDMO"). This dual role enables Synbio Powerlabs® to seamlessly bridge the gap between cutting-edge biotechnology research and real-world industrial applications, accelerating the commercialization of novel bio-based products. Its flagship product line, marketed under the Eternal® brand, features a diverse portfolio of high-quality, sustainable ingredients derived from fungi, serving multiple industries and applications.Gentle Tech (G-FAS & Gentle Farming)A frontier tech company developing sustainable, autonomous agricultural equipment. Focused on reducing environmental impact through innovations in materials science, information technologies, and alternative energy to maximize efficiency and minimize the carbon footprint. The business model includes G-FAS (selling ultra-light weight harvesting heads directly to farmers) and Gentle Farming (developing machinery for autonomy and intelligent management).Forward Looking StatementsThis press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Contact InformationPress & Media: comms@moolecscience.comInvestor Relations: ir@moolecscience.comSOURCE: Moolec Science SARelated Documents:Moolec Science Enters into Transformational Transaction Expanding Across Multiple Technology Platforms.pdf Copyright 2025 ACN Newswire via SeaPRwire.com.